Rockwell Medical, Inc. (RMTI)

Market Cap	38.82M
Revenue (ttm)	101.49M
Net Income (ttm)	-782,000
Shares Out	34.06M
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	253,622
Open	1.200
Previous Close	1.200
Day's Range	1.140 - 1.230
52-Week Range	1.140 - 5.150
Beta	1.56
Analysts	Strong Buy
Price Target	4.00 (+250.88%)
Earnings Date	Mar 20, 2025

About RMTI

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products,...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jan 27, 1998
• Employees: 237
• Stock Exchange: NASDAQ
• Ticker Symbol: RMTI
• Website: https://www.rockwellmed.com

Financial Performance

In 2024, Rockwell Medical's revenue was $101.49 million, an increase of 21.38% compared to the previous year's $83.61 million. Losses were -$782,000, -90.90% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for RMTI stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 250.88% from the latest price.

Price Target

$4.0

(250.88% upside)

Analyst Consensus: Strong Buy